HOME > TOP STORIES

TOP STORIES

REGULATORY Japan to Approve EquMet Generics, More Copycats toward June Listing

February 17, 2025
REGULATORY J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27

February 14, 2025
BUSINESS Regeneron to Upsize Japan Workforce after Libtayo Transfer

February 13, 2025
BUSINESS Cheplapharm Set to Expand LLP Deals to 20 APIs, Sees Opportunities Despite Headwinds

February 12, 2025
ORGANIZATION US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA

February 10, 2025
BUSINESS Bain Picks Up Mitsubishi Tanabe for Over 500 Billion Yen

February 10, 2025
BUSINESS AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies

February 7, 2025
BUSINESS Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon

February 6, 2025
REGULATORY Japan’s 1st Hemophilia B Gene Therapy Up for Panel Review on Feb. 19

February 6, 2025
COMMENTARY Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations

February 5, 2025
BUSINESS Astellas to Revamp Management in April, Consolidate R&D Functions

February 5, 2025
ACADEMIA Medical Society Says “No” to Discontinuation of Theodur Despite Supply Struggle

February 5, 2025
REGULATORY PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official

February 4, 2025
BUSINESS Daiichi Sankyo Assigns COO Okuzawa as CEO from April

February 3, 2025
BUSINESS Julie Kim Tapped to Take Over Helm of Takeda in 2026

January 31, 2025
BUSINESS Takeda CEO Weber to Retire Next Year, Succeeded by US Head

January 30, 2025
BUSINESS Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President

January 30, 2025
REGULATORY Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment

January 30, 2025
REGULATORY MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan

January 30, 2025
BUSINESS Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President

January 29, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…